Park Hee Chul, Pyo Hong Ryull, Shin Kyoo-Ho, Suh Chang Ok
Department of Radiation Oncology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Republic of Korea.
Oncology. 2003;64(4):346-52. doi: 10.1159/000070292.
We retrospectively evaluated the outcome of patients treated with radiotherapy, with or without surgery, for aggressive fibromatosis. The patterns of local failure were analyzed to determine the optimum radiation dose and volume for irradiation.
Twenty-four patients with histologically confirmed aggressive fibromatosis were treated with radiation therapy at the Yonsei Cancer Center between 1990 and 1998. The radiation dose per patient ranged from 39.6 to 59.4 Gy (mean: 49.4 Gy). The entire operative bed, with a generous margin, was included in the radiotherapy volume. Patients were considered as locally controlled if there was no evidence of the disease during their follow-up period, and if the tumors were stable for more than 2 years. The minimum duration of the follow-up period was 26 months, with a median of 69 months.
The actuarial 10-year recurrence-free and overall survival were 88.5 and 100%, respectively. Patients who had a recurrence were salvaged by combined surgery and re-irradiation. Recurrences developed only in patients who had a recurrent disease after surgery and were treated with an inadequate radiation volume. In 9 patients with a gross measurable disease, there were no in-field failures; these had been treated with a median of 50.4 Gy (range: 40-60 Gy) of radiation. Eight patients with a microscopic residual disease were also locally controlled with 41.4-59.4 Gy (median: 45 Gy) of radiation. No patient has developed either secondary malignancy or any serious radiation complications.
Radiotherapy for aggressive fibromatosis can be an effective treatment option for maintaining a disease-free status. As fibromatosis, with either a microscopic, or a gross residual disease, can be controlled with a moderate dose of radiation, adjuvant postoperative radiotherapy following surgical excision is recommended with the least sufficient margin to preserve good function and cosmesis. The geographic relationship may require a more precise definition; in addition, regardless of the existence of neighborhood normal tissue barriers, a wide coverage of the radiation volume may be needed.
我们回顾性评估了接受放疗(无论是否联合手术)治疗侵袭性纤维瘤病患者的治疗结果。分析局部复发模式以确定最佳放疗剂量和照射体积。
1990年至1998年间,24例经组织学确诊的侵袭性纤维瘤病患者在延世癌症中心接受了放射治疗。每位患者的放疗剂量为39.6至59.4 Gy(平均:49.4 Gy)。放疗体积包括整个手术床,并留有足够的边缘。如果患者在随访期间没有疾病证据,且肿瘤稳定超过2年,则认为患者局部得到控制。随访期最短为26个月,中位随访期为69个月。
精算10年无复发生存率和总生存率分别为88.5%和100%。复发患者通过联合手术和再次放疗挽救。复发仅发生在术后复发且放疗体积不足的患者中。9例有可测量大体病灶的患者,野内无复发;这些患者接受的放疗中位剂量为50.4 Gy(范围:40 - 60 Gy)。8例有镜下残留病灶的患者也通过41.4 - 59.4 Gy(中位剂量:45 Gy)的放疗实现了局部控制。没有患者发生继发性恶性肿瘤或任何严重的放疗并发症。
侵袭性纤维瘤病的放疗可以是维持无病状态的有效治疗选择。由于侵袭性纤维瘤病,无论是镜下还是大体残留病灶,都可以通过适度剂量的放疗得到控制,因此建议在手术切除后进行辅助性术后放疗,切除边缘应足够以保留良好功能和美观。可能需要更精确地定义解剖关系;此外,无论周围正常组织屏障是否存在,可能都需要广泛覆盖放疗体积。